tiprankstipranks
Trending News
More News >
Target Healthcare REIT Limited (GB:THRL)
LSE:THRL
UK Market

Target Healthcare REIT (THRL) AI Stock Analysis

Compare
42 Followers

Top Page

GB:THRL

Target Healthcare REIT

(LSE:THRL)

Select Model
Select Model
Select Model
Outperform 71 (OpenAI - 5.2)
Rating:71Outperform
Price Target:
118.00p
▲(20.53% Upside)
Action:ReiteratedDate:12/11/25
The overall stock score is driven by a solid valuation with a low P/E ratio and high dividend yield, despite concerns over declining cash flow growth and weak technical momentum.
Positive Factors
Stable rental-based business model
THRL’s core model of long-term leases to experienced operators creates predictable, contractually backed rental income. That durable cash flow base supports consistent distributions, reduces revenue volatility and underpins capital planning and portfolio reinvestment over the medium term.
Structural demand for healthcare properties
Secular demand for healthcare and specialist facilities drives long-term occupier need and lowers vacancy risk for care homes. This structural tailwind supports sustained rental demand, pricing power for in-demand assets and resilience to typical economic cycles over coming quarters.
Moderate leverage and healthy equity ratio
A moderate debt-to-equity position and healthy equity ratio provide financial flexibility for refinancing, acquisitions and support for distributions. This balanced leverage profile reduces refinancing risk and preserves capacity to invest as opportunities arise in the medium term.
Negative Factors
Declining free cash flow growth
Falling free cash flow growth constrains the REIT’s ability to fund acquisitions, capex and dividends from internal resources. Over time weaker FCF limits strategic flexibility, potentially forcing more external financing or dividend adjustments if the trend persists beyond several quarters.
Pressure on operating margins
Declining EBIT and EBITDA margins indicate rising operating costs or weaker rent economics and reduce cash available for distributions and reinvestment. If margin compression continues, it could erode profitability and the REIT’s ability to maintain yield and pursue growth.
Slowing EPS despite revenue growth
Modest revenue growth alongside a sizeable negative EPS trend suggests cost pressures, non-operating impacts or financing costs are weighing on earnings. Persistent EPS decline relative to revenue undermines retained earnings and may constrain capital allocation over the medium term.

Target Healthcare REIT (THRL) vs. iShares MSCI United Kingdom ETF (EWC)

Target Healthcare REIT Business Overview & Revenue Model

Company DescriptionTarget Healthcare REIT provide a range of tailored funding solutions to support operators to increase the provision of modern, purpose-built care homes across the UK.
How the Company Makes MoneyTarget Healthcare REIT generates revenue primarily through rental income from its portfolio of healthcare properties. The company leases these properties to experienced operators under long-term agreements, ensuring a stable and predictable income stream. Additionally, THRL benefits from property appreciation over time, which can enhance its overall asset value. The REIT may also engage in strategic partnerships with healthcare operators to optimize the performance of its properties, contributing to its financial performance. The demand for healthcare services and the growing need for specialized facilities further support the company's revenue potential.

Target Healthcare REIT Financial Statement Overview

Summary
Target Healthcare REIT shows stable revenue growth and profitability with a balanced financial structure. However, declining cash flow growth and operational efficiency are concerns.
Income Statement
75
Positive
The income statement shows a stable revenue growth rate of 3.07% in the latest year, with strong gross and net profit margins. However, there is a noticeable decline in EBIT and EBITDA margins compared to previous years, indicating potential pressure on operational efficiency.
Balance Sheet
70
Positive
The balance sheet reflects a moderate debt-to-equity ratio, indicating a balanced leverage position. The return on equity has been positive, although it has shown some fluctuations. The equity ratio remains healthy, suggesting a stable financial structure.
Cash Flow
65
Positive
Cash flow analysis reveals a decline in free cash flow growth, which could be a concern. However, the operating cash flow to net income ratio remains strong, indicating efficient cash generation relative to earnings.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue72.93M78.48M67.75M63.86M49.98M
Gross Profit64.84M78.48M60.14M56.55M44.18M
EBITDA59.59M58.00M0.000.000.00
Net Income60.84M73.02M-6.57M49.10M43.88M
Balance Sheet
Total Assets986.19M967.37M908.26M963.66M718.39M
Cash, Cash Equivalents and Short-Term Investments39.64M38.88M15.37M34.48M21.11M
Total Debt240.29M240.67M227.05M231.38M127.90M
Total Liabilities273.73M278.08M253.45M264.89M153.21M
Stockholders Equity712.46M689.29M654.81M698.77M565.18M
Cash Flow
Free Cash Flow41.10M42.34M29.66M30.39M24.96M
Operating Cash Flow41.10M42.34M29.66M30.39M24.96M
Investing Cash Flow-3.23M3.42M-3.55M-202.63M-43.58M
Financing Cash Flow-37.11M-22.24M-45.23M185.62M3.29M

Target Healthcare REIT Technical Analysis

Technical Analysis Sentiment
Positive
Last Price97.90
Price Trends
50DMA
101.66
Positive
100DMA
97.38
Positive
200DMA
96.14
Positive
Market Momentum
MACD
1.51
Positive
RSI
61.44
Neutral
STOCH
72.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:THRL, the sentiment is Positive. The current price of 97.9 is below the 20-day moving average (MA) of 105.60, below the 50-day MA of 101.66, and above the 200-day MA of 96.14, indicating a bullish trend. The MACD of 1.51 indicates Positive momentum. The RSI at 61.44 is Neutral, neither overbought nor oversold. The STOCH value of 72.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:THRL.

Target Healthcare REIT Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
10.898.68%6.15%4.86%-16.65%
71
Outperform
£2.81B14.907.01%7.30%0.96%
61
Neutral
£303.36M-6.81-10.89%8.16%-4.24%-273.62%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
48
Neutral
£107.62M-11.816.96%
48
Neutral
£148.75M-4.85-12.26%4.55%23.43%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:THRL
Target Healthcare REIT
106.80
27.12
34.04%
GB:PHP
Primary Health Properties plc R.E.I.T
108.30
22.80
26.67%
GB:RESI
Residential Secure Income
58.20
3.59
6.57%
GB:HOME
Home REIT PLC
9.10
-1.90
-17.27%
GB:SOHO
Triple Point Social Housing REIT PLC
77.10
24.29
46.00%
GB:LABS
Life Science Reit Plc
42.50
8.40
24.63%

Target Healthcare REIT Corporate Events

Business Operations and StrategyDividendsFinancial Disclosures
Target Healthcare REIT Boosts NAV and Prunes Portfolio as It Recycles Capital into Higher-Yield Care Homes
Positive
Feb 5, 2026

Target Healthcare REIT reported a 1.4% rise in EPRA Net Tangible Assets per share to 119.4p as at 31 December 2025, with a twelfth consecutive quarter of positive total returns driven by active portfolio recycling and inflation-linked rent reviews. The company completed the sale of nine care homes for £85.9m at an 11.6% premium to June 2025 carrying value and disposed of an additional asset at a similar premium, while redeploying more than half the proceeds into three modern, operational care homes in central Scotland and a forward-funded fourth asset, all at blended net initial yields above 6%. The portfolio now comprises 86 operational homes valued at £894.6m, with 99% rent collection, average rent cover of 2.0x on mature assets, a WAULT of 26.3 years, and 100% of properties rated EPC A or B, underscoring resilient cash flows and strong ESG credentials. Adjusted EPRA EPS was 1.69p for the quarter, fully covering the 1.508p dividend, and net LTV fell to 15.2% as proceeds are progressively redeployed, with around £100m of capital available and a growing pipeline of higher-yielding, purpose-built care home investments that are expected to lift leverage towards the 25% area.

The most recent analyst rating on (GB:THRL) stock is a Hold with a £115.00 price target. To see the full list of analyst forecasts on Target Healthcare REIT stock, see the GB:THRL Stock Forecast page.

Business Operations and StrategyShareholder Meetings
Target Healthcare REIT Secures Shareholder Approval at AGM
Positive
Dec 5, 2025

Target Healthcare REIT PLC announced that all resolutions proposed at its Annual General Meeting on December 4, 2025, were passed. This outcome reflects strong shareholder support and could positively impact the company’s strategic initiatives and market positioning, reinforcing its commitment to delivering value in the healthcare real estate sector.

The most recent analyst rating on (GB:THRL) stock is a Buy with a £1.05 price target. To see the full list of analyst forecasts on Target Healthcare REIT stock, see the GB:THRL Stock Forecast page.

Business Operations and StrategyM&A Transactions
Target Healthcare REIT Expands Portfolio with £45 Million Acquisition
Positive
Dec 1, 2025

Target Healthcare REIT has acquired three operational care homes and committed to a fourth in Central Scotland for £45 million, reinvesting proceeds from a recent disposal. This strategic move is expected to be earnings accretive and reflects a net initial yield over 6%, enhancing the company’s portfolio with long-term rental income security and ESG standards. The transaction highlights Target Healthcare’s ability to efficiently redeploy capital and strengthen its market position in the care home sector.

The most recent analyst rating on (GB:THRL) stock is a Buy with a £1.05 price target. To see the full list of analyst forecasts on Target Healthcare REIT stock, see the GB:THRL Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 11, 2025